Dorian A Rosen, PhD, (left) and Alban Gaultier, PhD, found last year that fluvoxamine may stop the deadly inflammation known as sepsis. The drug is now being tested as a protective measure for patients with COVID-19.
Dorian A Rosen, PhD, (left) and Alban Gaultier, PhD, found last year that fluvoxamine may stop the deadly inflammation known as sepsis. The drug is now being tested as a protective measure for patients with COVID-19.
